文章摘要
黄朝友,李 响,钱友良,戴 铁,赖 飞.地奥司明对前列腺增生伴前列腺炎患者HSP, CRP及PSA的影响[J].,2017,17(13):2508-2511
地奥司明对前列腺增生伴前列腺炎患者HSP, CRP及PSA的影响
Effect of Diosmin on the Serum Heat Shock Protein, C Reactive Protein and PSA Level in the Treatment of the Prostatic Hyperplasia with Prostatitis
投稿时间:2016-08-12  修订日期:2016-08-29
DOI:10.13241/j.cnki.pmb.2017.13.028
中文关键词: 前列腺炎  前列腺增生  C反应蛋白  热休克蛋白  PSA
英文关键词: Prostatitis  Prostatic hyperplasia  C reactive protein  Heat shock protein  PSA
基金项目:四川省卫生厅科研项目(060211)
作者单位
黄朝友 成都市第二人民医院 泌尿外科 四川 成都 610000 
李 响 四川大学华西医院 泌尿外科 四川 成都 610041 
钱友良 成都市第二人民医院 泌尿外科 四川 成都 610000 
戴 铁 成都市第二人民医院 泌尿外科 四川 成都 610000 
赖 飞 成都市第二人民医院 泌尿外科 四川 成都 610000 
摘要点击次数: 257
全文下载次数: 159
中文摘要:
      摘要 目的:探讨地奥斯明对前列腺增生伴前列腺炎患者血清热休克蛋白(HSP)、C反应蛋白(CRP)及血清PSA水平的影响。方法:选取已确诊为前列腺增生伴前列腺炎的患者39例,随机分为实验组及对照组。对照组19例,予普适泰片治疗;实验组20例,予地奥司明治疗。28天为一个治疗疗程。比较两组患者治疗前后热休克蛋白、C反应蛋白及血清PSA水平的变化。结果:实验组总有效率(95.0 %)高于对照组(78.9 %),差异具有统计学意义(P<0.05);与对照组比较,实验组热休克蛋白、C反应蛋白及血清PSA水平较低(P<0.05),慢性前列腺炎评分(NIH-CPSI)评分较低(P<0.05),不良反应发生率(10.0 %)低于对照组(31.6 %),差异存在统计学意义(P<0.05)。结论:地奥司明片可以明显改善男性前列腺增生伴前列腺炎患者的排尿困难及尿频尿急等症状,有效降低患者热休克蛋白、C反应蛋白及血清PSA水平。
英文摘要:
      ABSTRACT Objective: To investigate the effect of diosmin on the serum heat shock protein, C reactive protein and PSA level in the treatment of the prostatic hyperplasia with prostatitis. Methods: 39 patients with prostatic hyperplasia combined prostatitis from our hos- pital were selected and randomly divided into the control group and the experimental group. 19 cases in the control group were treated by Prostat Tablets and 20 cases in the experimental group were treated by diosmin. 28 days were for a treatment course. The heat shock pro- tein, C reactive protein and serum PSA level were compared between two groups before and after treatment. Results: The total effective rate of the experimental group (95 %) was higher than that of the control group (78.9 %), and the difference was statistically significant (P<0.05). Compared with the control group, the serum heat shock protein, C reactive protein and PSA level were lower in the experimen- tal group (P<0.05), and the NIH-CPSI score was lower (P<0.05). The incidence of adverse reaction (10 %) was lower than that of the control group (31.6 %), and the difference was statistically significant (P<0.05). Conclusion: Diosmin tablets can effectively relieve dy- suria and urinary urgency and other symptoms in the treatment of prostate hyperplasia with prostatitis, and significantly reduce the serum heat shock protein, C-reactive protein and PSA levels.
查看全文   查看/发表评论  下载PDF阅读器
关闭